Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich syndrome): Frequency, clinical implication, and prognosis.

angioedema hypereosinophilic syndrome lymphoma (T-cell, peripheral) recurrence treatment outcome

Journal

Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132

Informations de publication

Date de publication:
05 2023
Historique:
received: 31 08 2018
revised: 28 01 2019
accepted: 01 02 2019
medline: 19 4 2023
pubmed: 10 2 2019
entrez: 10 2 2019
Statut: ppublish

Résumé

Episodic angioedema with eosinophilia (EAE) (Gleich syndrome) is a rare disorder consisting of recurrent episodes of angioedema, hypereosinophilia, and frequent elevated serum IgM level. We conducted a retrospective multicenter nationwide study regarding the clinical spectrum and therapeutic management of patients with EAE in France. A total of 30 patients with a median age at diagnosis of 41 years (range, 5-84) were included. The median duration of each crisis was 5.5 days (range, 1-90), with swelling affecting mainly the face and the upper limbs. Total serum IgM levels were increased in 20 patients (67%). Abnormal T-cell immunophenotypes were detected in 12 patients (40%), of whom 5 (17%) showed evidence of clonal T-cell receptor gamma locus gene (TRG) rearrangement. The median duration of follow-up was 53 months (range, 31-99). The presence of an abnormal T-cell population was the sole factor associated with a shorter time to flare (hazard ratio, 4.15; 95% confidence interval, 1.18-14.66; P = .02). At last follow-up, 3 patients (10%) were able to have all treatments withdrawn and 11 (37%) were in clinical and biologic remission with less than 10 mg of prednisone daily. EAE is a heterogeneous condition that encompasses several disease forms. Although patients usually respond well to glucocorticoids, those with evidence of abnormal T-cell phenotype have a shorter time to flare.

Sections du résumé

BACKGROUND
Episodic angioedema with eosinophilia (EAE) (Gleich syndrome) is a rare disorder consisting of recurrent episodes of angioedema, hypereosinophilia, and frequent elevated serum IgM level.
METHODS
We conducted a retrospective multicenter nationwide study regarding the clinical spectrum and therapeutic management of patients with EAE in France.
RESULTS
A total of 30 patients with a median age at diagnosis of 41 years (range, 5-84) were included. The median duration of each crisis was 5.5 days (range, 1-90), with swelling affecting mainly the face and the upper limbs. Total serum IgM levels were increased in 20 patients (67%). Abnormal T-cell immunophenotypes were detected in 12 patients (40%), of whom 5 (17%) showed evidence of clonal T-cell receptor gamma locus gene (TRG) rearrangement. The median duration of follow-up was 53 months (range, 31-99). The presence of an abnormal T-cell population was the sole factor associated with a shorter time to flare (hazard ratio, 4.15; 95% confidence interval, 1.18-14.66; P = .02). At last follow-up, 3 patients (10%) were able to have all treatments withdrawn and 11 (37%) were in clinical and biologic remission with less than 10 mg of prednisone daily.
CONCLUSION
EAE is a heterogeneous condition that encompasses several disease forms. Although patients usually respond well to glucocorticoids, those with evidence of abnormal T-cell phenotype have a shorter time to flare.

Identifiants

pubmed: 30738125
pii: S0190-9622(19)30196-3
doi: 10.1016/j.jaad.2019.02.001
pii:
doi:

Substances chimiques

Immunoglobulin M 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e243-e250

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Noémie Abisror (N)

AP-HP, Hôpital Saint Antoine, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B) (DHU i2B), Faculté de Médecine Sorbonne Université, Paris, France. Electronic address: noemie.abisror@gmail.com.

Arsène Mekinian (A)

Sorbonne Université, Inserm U1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Département Biostatistique, Santé Publique, Information Médicale-Hôpital Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.

Agnès Dechartres (A)

Service de Médecine Interne, Université Versailles Saint-Quentin-en-Yvelines, Centre de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.

Matthieu Groh (M)

Service de Médecine Interne, Université Versailles Saint-Quentin-en-Yvelines, Centre de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.

Alice Berezne (A)

Service de Médecine Interne, CH Annecy Genevois, Annecy, France.

Nicolas Noel (N)

Department of Internal Medicine, Assistance-Publique Hôpitaux de Paris Paris XI University, Hôpital Bicêtre Le Kremlin-Bicêtre, France.

Chafika Morati (C)

Service de Médecine Interne, CH Annecy Genevois, Annecy, France.

Julien Haroche (J)

Department of Internal Medicine, French Reference Centre for Rare Autoimmune Systemic Diseases, e3m Institute, Assistance-Publique Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, and Paris VI University (UPMC), Sorbonne Universités, Paris, France.

Mathilde Hunault-Berger (M)

Maladies du Sang, CHU Angers, CRCINA, INSERM, Université de Nantes, Université d'Angers, Angers, France.

Christian Agard (C)

Service de Médecine Interne, CHU Hôtel-Dieu, Nantes, France.

Felix Ackermann (F)

Service de Médecine Interne, Université Versailles Saint-Quentin-en-Yvelines, Centre de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.

Loïk Geffray (L)

Service de médecine interne, Centre Hospitalier, Lisieux, France.

Pierre-Yves Jeandel (PY)

Service de Médecine Interne, Centre Hospitalier Universitaire de Nice, Nice, France.

Sébastien Trouillier (S)

Service de Médecine Interne, Centre Hospitalier d'Aurillac, Aurillac, France.

Thomas Quemeneur (T)

Département de Néphrologie et Département de Médecine Interne, Centre Hospitalier de Valenciennes, Valenciennes, France.

Jean-François Dufour (JF)

Service de Médecine Interne et Post-Urgence, Centre Hospitalier de Bourg-en-Bresse, Bourg-en-Bresse, France.

Isabelle Lamaury (I)

Inserm-CIC 1424 et Service de Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, France.

François Lhote (F)

Service de Médecine Interne, Hôpital de Saint-Denis, Saint-Denis, France.

Guillaume Lefèvre (G)

U995, LIRIC-Lille Inflammation Research International Center; INSERM, U995; Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares (Sclérodermie Systémique), Centre de Référence des Syndromes Hyperéosinophiliques (CEREO); and Institut d'Immunologie, CHU Lille, Université de Lille, Lille, France.

Olivier Fain (O)

AP-HP, Hôpital Saint Antoine, Service de Médecine Interne, Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B) (DHU i2B), Faculté de Médecine Sorbonne Université, Paris, France.

Jean Emmanuel Kahn (JE)

Service de Médecine Interne, Université Versailles Saint-Quentin-en-Yvelines, Centre de Référence des Syndromes Hyperéosinophiliques (CEREO), Hôpital Foch, Suresnes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH